Skip to main content

Table 4 MSNA data

From: Does moxonidine reduce Achilles tendon or musculoskeletal pain in women with polycystic ovarian syndrome? A secondary analysis of a randomised controlled trial

Data

Group

Pre-intervention

Post-intervention

2-way ANOVA p-value

Burst frequency (bursts/min)

Placebo

31.7 ± 11.0

30.0 ± 16.7

Group = 0.03*

Time-point = 0.34

Group x Time-point = 0.63

Moxonidine

25.2 ± 7.9

20.0 ± 6.0

Burst incidence (bursts/100HB)

Placebo

47.9 ± 13.1

46.3 ± 24.1

Group = 0.02*

Time-point = 0.52

Group x Time-point = 0.76

Moxonidine

37.4 ± 10.0

32.7 ± 10.1

Units/min

Placebo

1624 ± 697

1477 ± 989

Group = 0.03*

Time-point = 0.44

Group x Time-point = 0.93

Moxonidine

1162 ± 338

977 ± 304

Units/100HB

Placebo

2448 ± 877

2263 ± 1303

Group = 0.02*

Time-point = 0.54

Group x Time-point = 0.96

Moxonidine

1734 ± 429

1578 ± 460

  1. *significant difference